ATLANTA–(BUSINESS WIRE)–Georgia Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical trials for SYFOVRE, the first and only FDA-approved treatmen…
Author: Business Wire
University Retina Participate in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy
CHICAGO–(BUSINESS WIRE)–University Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical trials for SYFOVRE, the first and only FDA-approved treat…
Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023
FORT WORTH–(BUSINESS WIRE)–Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, March 9, 2023 to report financial results for the year ended December 31, 2022 and discuss recent corporate hig…
Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results
PARSIPPANY, N.J.–(BUSINESS WIRE)–Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2022 and provided a general business update.
National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2022 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2022, and is providing its outlook for fiscal…
Kopin Corporation Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program
WESTBOROUGH, Mass.–(BUSINESS WIRE)–Kopin Corporation (NASDAQ: KOPN), a leading provider of application-specific optical solutions for defense, enterprise, industrial, and consumer products has engaged international investor relations specialists MZ G…
Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference
PARSIPPANY, N.J.–(BUSINESS WIRE)–Iveric Bio announced that the Company will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023.
Lumata Health and Hadley Announce Partnership to Expand Access to Tools and Healthcare Resources for Vision Impaired Patients
RALEIGH, N.C. & OKLAHOMA CITY & WINNETKA, Ill.–(BUSINESS WIRE)–Lumata Health announces its partnership with Hadley to combine their resources serving patients experiencing vision loss.
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced top-line results from a 12-month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug, i…
Warby Parker Announces Fourth Quarter and Full Year 2022 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ended December 31, 2022. “Our team’s accom…
Alcon Reports Fourth Quarter and Full Year 2022 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Fourth Quarter and Full Year 2022 Results
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the su…
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
WATERTOWN, Mass. & NEW HAVEN, Conn.–(BUSINESS WIRE)–EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB…
Eye Care Center of Northern Colorado Selects End-to-End Ophthalmology Suite From ModMed for Its Facilities
BOCA RATON, Fla.–(BUSINESS WIRE)–Practice technology leader ModMed® today announced that Eye Care Center of Northern Colorado (ECCNC) will leverage ModMed to help deliver superior provider and patient experiences while helping to improve practice eff…
Zenni Scores First MLS Sponsorship – Becomes Official Eyewear of Major League Soccer’s Columbus Crew
NOVATO, Calif.–(BUSINESS WIRE)–Zenni Optical, the eyewear industry’s leading online retailer, announced today its first ever MLS partnership and will become the Official Eyewear of Major League Soccer’s Columbus Crew. The partnership extends Zenni’s …
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the advancement of two investigational new drug candidates, ADX‑246 and ADX‑248, to clinical testing, pending completion of U.S. Food and Drug Admini…
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financ…
Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023
PARSIPPANY, N.J.–(BUSINESS WIRE)–IVERIC bio today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023.
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quar…